Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It’s gonna pop or drop. Maybe both….,,
They can’t release the data at the conference……
without releasing it to the public too.
Well, they aren’t suppose to per Reg FD.
Maybe they’re waiting until 12-12:15.
The company remaining silent is hurting the pps......
IMO
Shorts trying to covering now it appears
The run up earlier this am to over $4 might have been a bit of a squeeze. I think the market was thinking a release of the data would have already occurred, hence the drop.
Thanks for the heads up!
16% short could see a squeeze !
Bivi $3.10 pending news / data !
I’m low-mid 3’s long term. I looking to see a PR by noon about Phase 3 results.
GL
$2.91 entry here phase 3 news watch
$40 is only a $1.5B market cap. Holding…….
If the Alzheimer’s drug works then we’re easily a buyout target above that.
In my opinion, of course.
Nice move on the data release.
Targets are way higher 15 25 50 all reasonable this year get it while it’s cheap
This one will float along and then #slurp they’re bought by LLY/PFE/MRK that’s the game plan here.
So many biopharma undervalued with great news already out..
The fda had got to change the process to approval.. we are stuck in mid evil times
This is probably one of the best plays given the real data -
Why doesn’t news on psirohsis success hit screen?
https://www.msn.com/en-us/health/medical/biovie-pauses-mid-stage-trial-for-ascites-candidate-after-encouraging-data/ar-AA18A4nK
BIVI
BioVie Inc
BioVie Inc (NASDAQ)
Search by Symbol or Name
Quote
Forum
Chart
Level 2
News
Trades
Options
Financials
Historical
5.70
0.33 (6.15%) Upgrade to Real-Time
Regular Market
Volume 137,638
Bid Price 5.69
View Full Level 2
Ask Price 5.71
News -
Day High 5.78
Low
1.325
52 Week Range
High
14.38
Day Low 5.41
Company Name Stock Ticker Symbol Market Type
BioVie Inc BIVI NASDAQ Common Stock
Price Change Change Percent Stock Price Last Traded Upgrade Icon
0.33 6.15% 5.70 12:42:54
Open Price Low Price High Price Close Price Prev Close
5.47 5.41 5.78 5.37
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
706 137,638 $ 5.59 $ 768,961 - 1.325 - 14.38
Last Trade Time Type Quantity Stock Price Currency
12:42:54 1 $ 5.69 USD
Period:
1 year
Draw Mode:
Line
Brutal pullback the last 2 days. Traders…..
have a short attention span.
due for a pullback, but who knows?
We have liftoff. Sum bi!ch what a……
move!
Congrats longs.
I’m still waiting on a pullback.
Bwahahahaha
At some point they’ll certainly need more……
money. They also have a big loan due in early 2024.
The CEO did say last week on Fox Bidness he hoped to have the Parkinson’s drug on the market within two years.
Right now I feel I missed the boat, but will certainly look for an entry on a big pullback.
But as someone said, I hope these guy ultimately are successful. Dementia is a terrible way to lose a loved one.
GL
$8.50 pre market….weeeee
Just saw this yesterday. Looks like it could drop back to 4-5 in the next week or two or even lower. If I understand it correctly they just started the phase 3 and may be looking at selling $20 million of stock soon. Or am I missing something.
Lol, I was hoping it would pull back…….
I will definitely keep watching.
Helluva run this week.
Damn $8.80....65% in 2 days. Oppenheimer upgrades price to $12
Looking for an entry point. Crazy price action today.
Agreed, it would be great to see it work. We’ve all had loved ones battle dementia.
GL
Bought in yesterday based on financial analyst recommendation. Don't normally do biotech but the fact that 3 of their major lines are entering phase 3 With stellar result so far... Worth taking a chance. Mother passed from horrific Case of dementia. If it stands up through phase 3 trials, It should be worth multiple billions. Don't even care if I make money as long as it ultimately works
TURDLICIOUS trying to bounce here, lets see if gets above my sell 3.47
2.95 BIVI= BOVINE EXCREMENT
4.83 down to 3.10 good call, I SOLD around 10k shares for .60 LO$$= -$6K
next time I need to look for offerings and shelf placements before diving in too deep
I thought I bought the dip but then the bottom fell out of the bottom and
kaBAM~!
you lose
errr I mean I lose
DUMPED looks like $20M offering coming in here https://ih.advfn.com/stock-market/NASDAQ/biovie-BIVI/stock-news/88959126/prospectus-filed-pursuant-to-rule-424b5-424b5
$20 million offering placed already or be on watch after a run here
CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that an interview with President and CEO Cuong Do will air on The RedChip Money Report(TM) on Bloomberg TV, March 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.
The RedChip Money Report(TM) is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today(TM). "The RedChip Money Report(TM)" delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
To view the interview segment, please visit:
RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the treatment of the first patient in the Company’s Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson’s disease patients.
The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD). Participants will be treated with carbidopa/levodopa and NE3107 or placebo. Forty patients with a defined PD medication “off state” will be randomized 1:1 placebo to: active NE3107 20 mg twice daily for 28 days. Safety assessments will look at standard measures of patient health and potential for drug-drug interactions affecting L-dopa pharmacokinetics and activity. Exploratory efficacy assessments will use the Motor Disease Society Unified Parkinson’s Disease Rating (MDS-UPDRS) parts 1-3, ON/OFF Diary, and Non-Motor Symptom Scale. Topline results are expected for the NM201 trial in mid-2022.
“Our NM201 study is designed to be an efficient, cost-effective assessment of the safety and pharmacokinetics profile, as well as the potential efficacy of NE3017 for the treatment of PD,” said Cuong V. Do, Chief Executive Officer of BioVie. “Enrollment of the first patient in our human development program is a significant milestone for BioVie, and we look forward to data readout for NM201 in mid-2022.”
In preclinical studies, NE3107 was shown to improve motor symptoms as effectively as L-dopa. When NE3107 was administered in combination with L-dopa, the combination demonstrated greater pro-motoric activity than NE3107 or L-dopa given alone. Furthermore, NE3107 in combination with L-dopa reduced the severity of L-dopa induced dyskinesia (LID) without decreasing the beneficial effect of the drug on motor symptoms. NE3107 treatment in monkeys preserved roughly twice as many dopaminergic neurons as vehicle-treated animals, suggesting that NE3107 may have neuroprotective properties.
Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), frontotemporal dementia and ALS. NE3107 is an oral small molecule, blood-brain permeable, compound with anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK- and NF?B-stimulated inflammation. No major safety signals have been observed in nonclinical safety studies, and the NE3107 adverse event profile has not differed from that of placebo in clinical studies conducted to date.
NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work testing the molecule in AD and PD patients. The company has an active Phase 3 trial studying NE3107 in Alzheimer’s Disease that is expected to have topline results by the end of 2022.
RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 202
RENO, Nev., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that the Company is partnering with the American Liver Foundation (ALF) in an educational campaign about chronic liver cirrhosis and its complications and to raise awareness among potential patients and healthcare providers about the Company’s Phase 2b Study of BIV201 (continuous infusion terlipressin). The trial— A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients with Cirrhosis and Refractory Ascites —is being conducted at ten prestigious research centers in the U.S. (NCT04112199).
RENO, Nev., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. (Collectively “the Avenue Venture Funds”) providing up to $25 million with the initial $15 million funded at the close on November 30, 2021.
“We are pleased to partner with the Avenue Venture Funds as we prepare for a catalyst-rich 2022, which includes anticipated top-line data from both our Phase 2b trial of BIV201 in refractory ascites and our Phase 3 trial of NE3107 in Alzheimer’s,” said Cuong Do, CEO of BioVie. “This non-dilutive funding provides us with the capital to take us through several key clinical milestones and to support continued advancement of our programs in additional indications as we initiate a Phase 2 trial of NE3107 in Parkinson’s disease that is expected to have topline data readout in the first half of 2022 and initiate a Phase 3 trial of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury.”
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
01/30/14
|
Type
|
Free
|
Moderators |
With no medications approved by the FDA specifically to treat ascites, the prognosis for these patients is very poor. Certain drugs which have been approved for other medical conditions (such as diuretics) combined with a salt restricted diet usually provide symptomatic relief in the initial stages of the disease. But as the ascites worsens their efficacy often diminishes. BioVie is working on a solution to address this critical unmet medical need.
Julie G. Anderson, Director. Anderson most recently served Catheter Connections, Inc. as its Vice President of Marketing until the company was sold last month. Previously she was Senior Director of Marketing for Durata Therapeutics, Inc., playing a key role in helping build the infrastructure and commercialization plan necessary to launch the novel antibiotic Dalvance. The team's efforts led to an acquisition of the company in 2014 by Actavis (now Allergan) in a deal valued at about $675 million. Prior to Durata, Julie worked for Sanofi-Synthelabo, Inc., Bayer Pharmaceuticals, and G.D. Searle in various marketing leadership positions. She originally trained as a nurse and earned a Masters of Management at the J.L. Kellogg Graduate School of Management at Northwestern University. As a critical care nurse, Julie treated patients at risk of death due to complications caused by chronic liver cirrhosis, and deeply understands the unmet medical need targeted by BioVie.
Hari Kumar, Director. Board of Directors as an independent director. In addition, Dr. Kumar purchased common shares of BioVie stock through a private placement. After earning a PhD in immunology in 1984, Dr. Kumar embarked upon a successful career in the biopharmaceutical industry. He held positions of increasing responsibility at Roche Pharma culminating in serving as Global Business Development Director, and in 2007 assumed the role of Chief Business Officer for Amira Pharmaceuticals. He led the sale of Amira to Bristol-Myers Squibb in 2011 for $475 million. He then served as Chief Executive Officer (CEO) for Panmira Pharmaceuticals LLC, which is developing anti-inflammatory compounds, and in 2013 became CEO for Adheron Therapeutics, which Roche Pharma acquired in 2015 for $580 million. Beyond his impressive track record, Dr. Kumar brings deep experience in fibrotic and liver diseases to the Company.
Press Releases: https://finance.yahoo.com/quote/bivi?p=bivi
In the News:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |